Avantor (NYSE:AVTR) Price Target Raised to $18.00

Avantor (NYSE:AVTR) had its price target hoisted by analysts at Stifel Nicolaus from $15.00 to $18.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage presently has a “hold” rating on the stock. Stifel Nicolaus‘s target price would indicate a potential upside of 8.33% from the company’s previous close.

Several other analysts also recently issued reports on AVTR. Evercore set a $17.00 price objective on Avantor in a research report on Wednesday. Barclays reiterated an “underweight” rating and set a $16.00 price objective on shares of Avantor in a research report on Thursday. Royal Bank Of Canada reissued a “sector perform” rating and issued a $17.00 target price on shares of Avantor in a research note on Wednesday. Wells Fargo & Company upped their target price on shares of Avantor from $14.00 to $16.00 and gave the company an “overweight” rating in a report on Thursday, July 30th. Finally, UBS Group began coverage on shares of Avantor in a report on Wednesday, September 9th. They issued a “neutral” rating and a $16.00 target price on the stock. Two equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $14.34.

Avantor Stock Down 3.0%

AVTR stock opened at $16.62 on Thursday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.78 and a quick ratio of 1.18. The company’s 50 day simple moving average is $15.40 and its 200-day simple moving average is $11.20. Avantor has a 12 month low of $7.26 and a 12 month high of $17.45. The firm has a market capitalization of $11.24 billion, a PE ratio of -19.78, a P/E/G ratio of 9.83 and a beta of 0.94.

Avantor (NYSE:AVTR) last announced its earnings results on Wednesday, October 28th. The company reported $0.22 EPS for the quarter, beating analysts’ consensus estimates of $0.21 by $0.01. The firm had revenue of $1.70 billion for the quarter, compared to analysts’ expectations of $1.64 billion. Avantor had a positive return on equity of 9.92% and a negative net margin of 8.81%. Avantor’s quarterly revenue was up 4.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.22 EPS. Equities analysts expect that Avantor will post 0.81 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Avantor

Several hedge funds have recently modified their holdings of AVTR. GSA Capital Partners LLP purchased a new position in Avantor during the second quarter worth approximately $800,000. Oppenheimer Asset Management Inc. purchased a new stake in shares of Avantor during the 2nd quarter valued at $805,000. Assenagon Asset Management S.A. increased its holdings in shares of Avantor by 425.0% during the 2nd quarter. Assenagon Asset Management S.A. now owns 556,871 shares of the company’s stock worth $5,513,000 after buying an additional 450,801 shares during the last quarter. Freestone Grove Partners LP acquired a new stake in shares of Avantor during the 2nd quarter worth $56,577,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Avantor in the 2nd quarter worth $1,922,000. 95.08% of the stock is owned by institutional investors and hedge funds.

More Avantor News

Here are the key news stories impacting Avantor this week:

• Positive Sentiment: Avantor reported third-quarter net sales of $1.698 billion, up 4.6% year over year, with organic growth of 5.2%. Revenue exceeded the $1.64 billion consensus estimate, while adjusted EPS of $0.22 topped expectations by $0.01. Avantor Reports Third Quarter 2026 Results
• Positive Sentiment: Both major business segments returned to growth, supporting the company’s outlook and suggesting improving demand across its life sciences and advanced technology markets. Avantor Q3 2026 Earnings: Revenue Beats Estimates as Both Segments Return to Growth
• Positive Sentiment: Management raised its full-year 2026 organic revenue-growth, adjusted EPS and free-cash-flow guidance, a potentially important catalyst for earnings estimates and investor confidence. Avantor Reports Third-Quarter and Nine-Month Results
• Neutral Sentiment: GAAP diluted EPS was $0.30, but the company remained unprofitable on a net-margin basis, which may limit the market’s reaction to the adjusted earnings beat.
• Negative Sentiment: Barclays reiterated a Sell rating and a $15 price target. That target is below the stock’s recent trading range and may reinforce concerns that the shares have moved ahead of near-term fundamentals. Barclays Keeps Sell Rating for Avantor

About Avantor

Avantor, Inc is a global provider of mission-critical products and services used in the life sciences, healthcare, education, and advanced technology industries. The company supplies chemicals, reagents, laboratory consumables, equipment, and other materials used in research, development, manufacturing, and quality-control activities.

Avantor also provides specialized solutions for biopharmaceutical production, including materials and services that support drug development, biologics manufacturing, and other bioprocessing applications.